Rakovina Therapeutics (TSXV:RKV) Debt-to-Equity : 0.46 (As of Mar. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Rakovina Therapeutics Debt-to-Equity?

Rakovina Therapeutics's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was C$0.00 Mil. Rakovina Therapeutics's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was C$1.35 Mil. Rakovina Therapeutics's Total Stockholders Equity for the quarter that ended in Mar. 2024 was C$2.94 Mil. Rakovina Therapeutics's debt to equity for the quarter that ended in Mar. 2024 was 0.46.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Rakovina Therapeutics's Debt-to-Equity or its related term are showing as below:

TSXV:RKV' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.26 Med: 0.33 Max: 0.46
Current: 0.46

During the past 3 years, the highest Debt-to-Equity Ratio of Rakovina Therapeutics was 0.46. The lowest was 0.26. And the median was 0.33.

TSXV:RKV's Debt-to-Equity is ranked worse than
73.4% of 1060 companies
in the Biotechnology industry
Industry Median: 0.14 vs TSXV:RKV: 0.46

Rakovina Therapeutics Debt-to-Equity Historical Data

The historical data trend for Rakovina Therapeutics's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Rakovina Therapeutics Debt-to-Equity Chart

Rakovina Therapeutics Annual Data

Trend

Dec21

Dec22

Dec23

Debt-to-Equity

0.36

Rakovina Therapeutics Quarterly Data
	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Debt-to-Equity	Get a 7-Day Free Trial								-	0.26	0.30	0.36	0.46

Competitive Comparison of Rakovina Therapeutics's Debt-to-Equity

For the Biotechnology subindustry, Rakovina Therapeutics's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Rakovina Therapeutics's Debt-to-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Rakovina Therapeutics's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Rakovina Therapeutics's Debt-to-Equity falls into.

Rakovina Therapeutics Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Rakovina Therapeutics's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0	+	1.333)	/	3.66
	=	0.36

Rakovina Therapeutics's Debt to Equity Ratio for the quarter that ended in Mar. 2024 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0	+	1.353)	/	2.941
	=	0.46

Rakovina Therapeutics (TSXV:RKV) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Rakovina Therapeutics Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Rakovina Therapeutics's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Rakovina Therapeutics (TSXV:RKV) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Rakovina Therapeutics Inc (TSXV:RKV) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

RKVTF:USA

Address

8 Smithe Mews, Suite 2201, Vancouver, BC, CAN, V6B 0A5

Website

https://www.rakovinatherapeutics.com

Rakovina Therapeutics Inc is engaged in drug discovery research, preclinical and clinical development, and regulatory affairs necessary to advance breakthrough innovations to become potential life-changing treatments in the oncology field. Its oncology pipeline has the potential to deliver biomarker-driven treatments for patients across multiple tumor types. Some f its products in the pipeline include kt-2000 Next Generation PARP-inhibitors, kt-3000 Dual Action DDR-inhibitors, and kt-4000 DNA Damaging DDR-inhibitors.

Executives

Alfredo De Lucrezia

Director, Senior Officer

Rakovina Therapeutics (TSXV:RKV) Headlines

No Headlines